https://doi.org/10.4081/reumatismo.2021.1453
Psoriasis and family history of psoriasis may not affect disease severity of rheumatoid arthritis
Submitted: 8 September 2021
Accepted: 25 December 2021
Published: 7 February 2022
Accepted: 25 December 2021
Abstract Views: 5391
PDF: 583
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
The incidence of psoriasis in patients with rheumatoid arthritis (RA) is higher than in the general population. In addition, psoriasis may negatively affect the severity of rheumatological diseases in patients with autoinflammatory or autoimmune diseases. In this study, we evaluated the effect of psoriasis or a family history of psoriasis on the characteristics of RA. This is a cross-sectional study. We included 737 RA patients who met the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) RA Classification Criteria, but did not meet the CASPAR psoriatic arthritis criteria. Subsequently, we compared disease activity, the need for biologic therapy, the number of conventional synthetic disease-modifying anti-rheumatic drugs taken, the frequency of erosive disease and extra-articular involvement, glucocorticoid doses and the Stanford Health Assessment Questionnaire scores between patients with and without a history of psoriasis, and patients with and without a family history of psoriasis. Thirteen (1.8%) patients had psoriasis, while 58 (7.9%) had a family history of psoriasis in first- or seconddegree relatives. All outcome parameters were found to be similar between the groups. We show that concomitant psoriasis has no effect on the evaluated disease characteristics of RA.
Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016; 388: 2023-38.
DOI: https://doi.org/10.1016/S0140-6736(16)30173-8
Lequerre T, Rottenberg P, Derambure C, et al. Predictors of treatment response in rheumatoid arthritis. Joint Bone Spine. 2019; 86: 151-8.
DOI: https://doi.org/10.1016/j.jbspin.2018.03.018
Schlager L, Loiskandl M, Aletaha D, Radner H. Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. Rheumatology (Oxford). 2020; 59: 324-34.
DOI: https://doi.org/10.1093/rheumatology/kez278
Turesson C, Eberhardt K, Jacobsson LT, Lindqvist E. Incidence and predictors of severe extra-articular disease manifestations in an early rheumatoid arthritis inception cohort. Ann Rheum Dis. 2007; 66: 1543-4.
DOI: https://doi.org/10.1136/ard.2007.076521
Abramkin AA, Lisitsyna TA, Veltishchev DY, et al. [Depression and severity of articular destruction in patients with rheumatoid arthritis]. Ter Arkh. 2020; 92: 22-32.
DOI: https://doi.org/10.26442/00403660.2020.05.000624
Garip Y, Eser F, Bodur H. Comorbidities in Turkish patients with rheumatoid arthritis: association with the health-related quality of life in terms of disease activity, functional and radiological status, severity of pain, and social and emotional functioning. Acta Reumatol Portuguesa. 2016; 41: 344-9.
Ajeganova S, Andersson ML, Hafstrom I, Group BS. Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset. Arthritis Care Res (Hoboken). 2013; 65: 78-87.
DOI: https://doi.org/10.1002/acr.21710
Boehncke WH, Schon MP. Psoriasis. Lancet. 2015; 386: 983-94.
DOI: https://doi.org/10.1016/S0140-6736(14)61909-7
Erden A, Batu ED, Seyhoglu E, et al. Increased psoriasis frequency in patients with familial Mediterranean fever. Ups J Med Sci. 2018; 123: 57-61.
DOI: https://doi.org/10.1080/03009734.2017.1423425
Millns JL, Muller SA. The coexistence of psoriasis and lupus erythematosus. An analysis of 27 cases. Arch Dermatol. 1980; 116: 658-63.
DOI: https://doi.org/10.1001/archderm.116.6.658
Solmaz D, Bakirci S, Kimyon G, et al. Impact of having family history of psoriasis or psoriatic arthritis on psoriatic disease. Arthritis Care Res (Hoboken). 2020; 72: 63-8.
DOI: https://doi.org/10.1002/acr.23836
Martin A, Thatiparthi A, Liu J, Wu JJ. Association between psoriasis and rheumatoid arthritis in a nationally representative population in the United States. J Am Acad Dermatol. 2021 [Epub ahead of print].
DOI: https://doi.org/10.1016/j.jaad.2021.06.841
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62: 2569-81.
DOI: https://doi.org/10.1002/art.27584
Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006; 54: 2665-73.
DOI: https://doi.org/10.1002/art.21972
Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38: 44-8.
DOI: https://doi.org/10.1002/art.1780380107
van der Heijde D, van der Helm-van Mil AH, Aletaha D, et al. EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. Ann Rheum Dis. 2013; 72: 479-81.
DOI: https://doi.org/10.1136/annrheumdis-2012-202779
Kucukdeveci AA, Sahin H, Ataman S, et al. Issues in cross-cultural validity: example from the adaptation, reliability, and validity testing of a Turkish version of the Stanford Health Assessment Questionnaire. Arthritis Rheum. 2004; 51: 14-9.
DOI: https://doi.org/10.1002/art.20091
Liu Y, Helms C, Liao W, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet. 2008; 4: e1000041.
DOI: https://doi.org/10.1371/journal.pgen.1000041
Lonnberg AS, Skov L, Skytthe A, et al. Heritability of psoriasis in a large twin sample. Br J Dermatol. 2013; 169: 412-6.
DOI: https://doi.org/10.1111/bjd.12375
Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nature Revi Dis Primers. 2016; 2: 16082.
DOI: https://doi.org/10.1038/nrdp.2016.82
Nordang GB, Flam ST, Maehlen MT, et al. HLA-C alleles confer risk for anti-citrullinated peptide antibody-positive rheumatoid arthritis independent of HLA-DRB1 alleles. Rheumatology (Oxford). 2013; 52: 1973-82.
DOI: https://doi.org/10.1093/rheumatology/ket252
Zhang Y, Zhang H, Huang Y, et al. Human leukocyte antigen (HLA)-C polymorphisms are associated with a decreased risk of rheumatoid arthritis. Mol Biol Rep. 2014; 41: 4103-8.
DOI: https://doi.org/10.1007/s11033-014-3280-9
Nishimura WE, Sachetto Z, Costallat LT, et al. The role of KIR2DL3/HLA-C*0802 in Brazilian patients with rheumatoid vasculitis. Clinics. 2015; 70: 408-12.
DOI: https://doi.org/10.6061/clinics/2015(06)04
Velarde-de la Cruz EE, Sanchez-Hernandez PE, Munoz-Valle JF, et al. KIR2DL2 and KIR2DS2 as genetic markers to the methotrexate response in rheumatoid arthritis patients. Immunopharmacol Immunotoxicol. 2016; 38: 303-9.
DOI: https://doi.org/10.1080/08923973.2016.1194429
Goh LL, Yong MY, See WQ, et al. NLRP1, PTPN22 and PADI4 gene polymorphisms and rheumatoid arthritis in ACPA-positive Singaporean Chinese. Rheumatol Int. 2017; 37: 1295-302.
DOI: https://doi.org/10.1007/s00296-017-3762-x
Abbasifard M, Imani D, Bagheri-Hosseinabadi Z. PTPN22 gene polymorphism and susceptibility to rheumatoid arthritis (RA): Updated systematic review and meta-analysis. J Gene Med. 2020; 22: e3204.
DOI: https://doi.org/10.1002/jgm.3204
Rahman P, Beaton M, Schentag CT, Gladman DD. Accuracy of self-reported family history in psoriatic arthritis. J Rheumatol. 2000; 27: 824-5.
How to Cite
Şen, N., Mercan, R., Geçmez, G., Ediz, B., Volkan, O., Yilmaz-Oner, S., & Tezcan, M. (2022). Psoriasis and family history of psoriasis may not affect disease severity of rheumatoid arthritis. Reumatismo, 73(4). https://doi.org/10.4081/reumatismo.2021.1453
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- C. Gioia, A. Picchianti Diamanti, R. Perricone, M.S. Chimenti, A. Afeltra, L. Navarini, A. Migliore, U. Massafra, V. Bruzzese, P. Scolieri, C. Meschini, M. Paroli, R. Caccavale, P. Scapato, R. Scrivo, F. Conti, B. Laganà, M. Di Franco, Anti-tumor necrosis factor α: originators versus biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies , Reumatismo: Vol. 75 No. 4 (2023)
- L. Degli Esposti, V. Perrone, D. Sangiorgi, L. Sinigaglia, Assessment of patients affected by rheumatoid arthritis eligible for biotechnological agents and evaluation of their healthcare resource utilization and related costs , Reumatismo: Vol. 73 No. 1 (2021)
- Z. Ahmadinejad, R. Assari, N. Ayoobi Yazdi, S.-H. Mazloomi, P. Javanshayani, H. Khalili Afousi, V. Ziaee, COVID-19 pandemic and biological therapy in rheumatologic disorders: how to deal with? , Reumatismo: Vol. 72 No. 3 (2020)
- F. Saccon, M. Gatto, M. Larosa, F. Ometto, M. Felicetti, R. Padoan, M. Zen, Diagnostic and prognostic role of renal histopathology in rheumatic diseases , Reumatismo: Vol. 70 No. 3 (2018): Monographic issue on Histopathology in Rheumatic Diseases
- A. Ciocci, L. Buratti, G. Coari, M. Di Franco, A.M. Iagnocco, M.T. Mauceri, A. Serio, Rheumatoid arthritis: frequency of hospitalization and evaluation of economic burden , Reumatismo: Vol. 53 No. 3 (2001)
- M. Fabris, B. Tolusso, E. Gremese, P. Tomietto, G. Ferraccioli, Analysis of the kinetic of expression of tristetraprolin and HuR by rheumatoid arthritis patients pheripheral blood mononuclear cells stimulated with lipopolysaccharide , Reumatismo: Vol. 56 No. 2 (2004)
- R. Herrera-Esparza, E. Avalos-Diaz, Infliximab treatment in a case of rheumatoid scleromalacia perforans , Reumatismo: Vol. 61 No. 3 (2009)
- P. Caramaschi, S. Pieropan, A. Volpe, A. Carletto, L.M Bambara, D. Biasi, Sustained response to infliximab treatment in two cases of early rheumatoid arthritis that has been maintained after drug withdrawal , Reumatismo: Vol. 60 No. 3 (2008)
- A. Spadaro, M.L. Sorgi, R. Scrivo, A. Picarelli, M. Di Tola, L. Sabbatella, E. Taccari, Anti-tissue transglutaminase antibodies in inflammatory and degenerative arthropathies , Reumatismo: Vol. 54 No. 4 (2002)
- F. Iannuzzella, G. Garini, Current therapeutic strategies for HCV-associated cryoglobulinemia , Reumatismo: Vol. 60 No. 3 (2008)
<< < 25 26 27 28 29 30 31 32 33 34 > >>
You may also start an advanced similarity search for this article.
